Health Care [ 5/12 ] | Pharmaceuticals [ 21/75 ]
NASDAQ | Common Stock
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases.
Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees.
Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 26 | -0.30 Increased by +45.45% | -0.34 Increased by +12.23% |
| Nov 6, 25 | -0.37 Increased by +65.42% | -0.45 Increased by +17.78% |
| Aug 7, 25 | -0.46 Increased by +36.99% | -0.46 |
| Jun 6, 25 | -0.42 Decreased by -250.00% | -0.50 Increased by +16.00% |
| Mar 4, 25 | -0.55 Decreased by -885.71% | -0.56 Increased by +1.79% |
| Nov 7, 24 | -1.07 Decreased by -456.67% | -0.70 Decreased by -52.86% |
| Aug 8, 24 | -0.73 Decreased by -335.48% | -0.73 |
| May 9, 24 | -0.12 Decreased by -700.00% | -0.01 Decreased by -1.10 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Increased by +100.00% | -33.00 M Increased by +12.11% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by -100.00% | -34.39 M Increased by +52.70% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Increased by +100.00% | -41.44 M Increased by +42.99% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by -100.00% | -35.91 M Increased by +69.77% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | -665.00 K Decreased by -100.61% | -37.55 M Decreased by -893.62% | Increased by +5.65 K% Increased by +129.32 K% |
| Sep 30, 24 | 416.00 K Decreased by -99.59% | -72.70 M Decreased by -447.98% | Decreased by -17.48 K% Decreased by -86.00 K% |
| Jun 30, 24 | -1.02 M Decreased by -101.04% | -72.70 M Decreased by -429.35% | Increased by +7.11 K% Increased by +31.52 K% |
| Mar 31, 24 | 88.64 M Increased by +24.10% | -118.79 M Decreased by -7.65 K% | Decreased by -134.01% Decreased by -6.19 K% |